Statements

Therapeutic response

Precision oncology relationships for therapeutic response.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Afatinib	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	FDA
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (+)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (+)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (+)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (+)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (+)	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (+)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (+)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (+)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	FDA
Sensitivity (+)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	FDA
Sensitivity (+)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (+)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (+)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	FDA
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	FDA
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	FDA
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	FDA
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (+)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	FDA
Sensitivity (+)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (+)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (+)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (+)	dMMR	Endometrial Carcinoma	Dostarlimab	FDA
Sensitivity (+)	dMMR	Any solid tumor	Dostarlimab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (+)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (+)	ER positive, ESR1 oncogenic variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant	FDA
Sensitivity (+)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	FDA
Sensitivity (+)	v::NTRK1	Any solid tumor	Entrectinib	FDA
Sensitivity (+)	v::NTRK2	Any solid tumor	Entrectinib	FDA
Sensitivity (+)	v::NTRK3	Any solid tumor	Entrectinib	FDA
Sensitivity (+)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (+)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (+)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (+)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (+)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	FGFR2::v	Intrahepatic Cholangiocarcinoma	Futibatinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (+)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (+)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (+)	FLT3-ITD	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835Y	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835A	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835E	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835H	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835N	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835S	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	FLT3 p.D835V	Acute Lymphoid Leukemia	Gilteritinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (+)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (+)	KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	FDA
Sensitivity (+)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	FDA
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (+)	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (+)	FGFR2::v	Cholangiocarcinoma	Infigratinib	FDA
Sensitivity (+)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	FDA
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (+)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	FDA
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (+)	v::NTRK1	Any solid tumor	Larotrectinib	FDA
Sensitivity (+)	v::NTRK2	Any solid tumor	Larotrectinib	FDA
Sensitivity (+)	v::NTRK3	Any solid tumor	Larotrectinib	FDA
Sensitivity (+)	5q deletion	Myelodysplastic Syndromes	Lenalidomide	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Margetuximab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Eribulin, Margetuximab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Gemcitabine, Margetuximab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Margetuximab, Vinorelbine	FDA
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Neratinib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib	FDA
Sensitivity (+)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (+)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab	FDA
Sensitivity (+)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (+)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (+)	dMMR	Any solid tumor	Pembrolizumab	FDA
Sensitivity (+)	MSI-H	Any solid tumor	Pembrolizumab	FDA
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (+)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab	FDA
Sensitivity (+)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	FDA
Sensitivity (+)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (+)	MSI-L	Endometrial Carcinoma	Lenvatinib, Pembrolizumab	FDA
Sensitivity (+)	pMMR	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (+)	MSI-H	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (+)	TMB-H (>= 10 mutations / Mb)	Any solid tumor	Pembrolizumab	FDA
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	FDA
Sensitivity (+)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (+)	FGFR2::v	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (+)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (+)	FGFR1 rearrangements	Myeloid/Lymphoid Neoplasms	Pemigatinib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine	FDA
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	FDA
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	FDA
Sensitivity (+)	v::RET	Non-Small Cell Lung Cancer	Pralsetinib	FDA
Sensitivity (+)	v::RET	Papillary Thyroid Cancer	Pralsetinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	FDA
Sensitivity (+)	v::NTRK1	Any solid tumor	Repotrectinib	FDA
Sensitivity (+)	v::NTRK2	Any solid tumor	Repotrectinib	FDA
Sensitivity (+)	v::NTRK3	Any solid tumor	Repotrectinib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (+)	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (+)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	FDA
Sensitivity (+)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib	FDA
Sensitivity (+)	v::RET	Anaplastic Thyroid Cancer	Selpercatinib	FDA
Sensitivity (+)	v::RET	Any solid tumor	Selpercatinib	FDA
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	FDA
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	EZH2 p.Y646N	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.Y646F	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.Y646H	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.Y646S	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.Y646C	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.A862G	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	EZH2 p.A692V	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (+)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (+)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (+)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (+)	ERBB2 oncogenic variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan	FDA
Sensitivity (+)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	FDA
Sensitivity (+)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab deruxtecan	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	FDA
Sensitivity (+)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib	FDA
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (+)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (+)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine	FDA
Sensitivity (+)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine	FDA
Sensitivity (+)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine	FDA
Sensitivity (+)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (+)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab	FDA
Sensitivity (+)	IDH1 p.R132C	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172K	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172M	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172G	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172S	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172W	Astrocytoma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (+)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (+)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (+)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (+)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab	FDA
Sensitivity (+)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab	FDA
Sensitivity (+)	HER2-positive	Cholangiocarcinoma	Zanidatamab	FDA
Sensitivity (+)	v::NRG1	Non-Small Cell Lung Cancer	Zenocutuzumab	FDA
Sensitivity (+)	v::NRG1	Pancreatic Adenocarcinoma	Zenocutuzumab	FDA
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Ensartinib	FDA
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (+)	t(KMT2A;v)	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (+)	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (+)	t(KMT2A;v)	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (+)	t(KMT2A;v)	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (+)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (+)	NPM1 p.W288Cfs*12	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (+)	NPM1 p.W288Cfs*12	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (+)	NPM1 p.W288Cfs*12	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (+)	TSC1 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (+)	TSC2 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (+)	TSC1 oncogenic variants	Anaplastic Thyroid Cancer	Everolimus	FDA
Sensitivity (+)	TSC2 oncogenic variants	Anaplastic Thyroid Cancer	Everolimus	FDA
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Taletrectinib	FDA
Sensitivity (+)	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin	FDA
Sensitivity (+)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (+)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (+)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (+)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (+)	HER2-negative, PR positive	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib	FDA
Sensitivity (+)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib	FDA
Sensitivity (+)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (+)	CD30 +	Angioimmunoblastic T-Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (+)	CD30 +	Peripheral T-Cell lymphoma, NOS	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (+)	CD30 +	Mycosis Fungoides	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	HC
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	HC
Sensitivity (+)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (+)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (+)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (+)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (+)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (+)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	HC
Sensitivity (+)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (+)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (+)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (+)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant	HC
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Afatinib	HC
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Afatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (+)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (+)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (+)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (+)	KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	HC
Sensitivity (+)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	HC
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Paclitaxel, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	HC
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	HC
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab	HC
Sensitivity (+)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (+)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (+)	dMMR	Endometrial Carcinoma	Dostarlimab	HC
Sensitivity (+)	MSI-H	Endometrial Carcinoma	Dostarlimab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Pembrolizumab	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Pembrolizumab	HC
Sensitivity (+)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	HC
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	HC
Sensitivity (+)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	HC
Sensitivity (+)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	HC
Sensitivity (+)	dMMR	Any solid tumor	Pembrolizumab	HC
Sensitivity (+)	MSI-H	Any solid tumor	Pembrolizumab	HC
Sensitivity (+)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	HC
Sensitivity (+)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	HC
Sensitivity (+)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	HC
Sensitivity (+)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	HC
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (+)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	HC
Sensitivity (+)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	HC
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	HC
Sensitivity (+)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	HC
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Trametinib	HC
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (+)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin	HC
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Nivolumab	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HC
Sensitivity (+)	FGFR2::v	Cholangiocarcinoma	Pemigatinib	HC
Sensitivity (+)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (+)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	HC
Sensitivity (+)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib	HC
Sensitivity (+)	v::RET	Papillary Thyroid Cancer	Selpercatinib	HC
Sensitivity (+)	5q deletion	Myelodysplastic Syndromes	Lenalidomide	HC
Sensitivity (+)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HC
Sensitivity (+)	CD20 +	Follicular Lymphoma	Rituximab	HC
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	HC
Sensitivity (+)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HC
Sensitivity (+)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	HC
Sensitivity (+)	v::NTRK1	Any solid tumor	Entrectinib	HC
Sensitivity (+)	v::NTRK2	Any solid tumor	Entrectinib	HC
Sensitivity (+)	v::NTRK3	Any solid tumor	Entrectinib	HC
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (+)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	HC
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (+)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	HC
Sensitivity (+)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Dabrafenib	HC
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	HC
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	HC
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	HC
Sensitivity (+)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (+)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (+)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel	HC
Sensitivity (+)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	HC
Sensitivity (+)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	HC
Sensitivity (+)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (+)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	HC
Sensitivity (+)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	HC
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	HC
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (+)	v::NTRK1	Any solid tumor	Larotrectinib	HC
Sensitivity (+)	v::NTRK2	Any solid tumor	Larotrectinib	HC
Sensitivity (+)	v::NTRK3	Any solid tumor	Larotrectinib	HC
Sensitivity (+)	IDH1 p.R132C	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132G	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132H	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132L	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132S	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172K	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172M	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172G	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172S	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172W	Astrocytoma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	HC
Sensitivity (+)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	HC
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	HC
Sensitivity (+)	FLT3 p.D835A	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835E	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835H	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835N	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835S	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835V	Acute Lymphoid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (+)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (+)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	HC
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	HC
Sensitivity (+)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib	HC
Sensitivity (+)	BRAF p.V600K	Melanoma	Vemurafenib	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	HC
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	HC
Sensitivity (+)	H3-3A p.K27M	Diffuse Midline Glioma	Dordaviprone	FDA
Sensitivity (+)	ER positive, ESR1 oncogenic variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant	FDA
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib	FDA
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib	FDA
Sensitivity (+)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib	FDA
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib	FDA
Sensitivity (+)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib	FDA
Sensitivity (+)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (+)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (+)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (+)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA